Abstract
Secretory phospholipase A2 group IIA (sPLA2-IIA) is an enzyme that hydrolyzes the sn-2 ester bond in glyceroacyl phospholipids present in lipoproteins and cell membranes. As many immunohistochemical studies reveal that the high expression of sPLA2-IIA in the tumorous tissue or plasma of cancer patients, though low expression in other cases, the enzyme is considered highly relevant with cancer development. Effort has been made to establish the mechanism of how sPLA2- IIA is involved in various cancers in order to understand its pathogenic role and to utilize it as a target for cancer diagnosis and therapy. This article specifically reviews recent studies regarding the relevance of sPLA2-IIA with various cancers and reported inhibitors of the protein.
Keywords: Cancer incidence, cell membranes, inhibitors, lipoproteins, sPLA2-IIA, therapeutic strategy.
Medicinal Chemistry
Title:A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Volume: 13 Issue: 7
Author(s): Juan Chen, Long Ye*, Yu Sun and Yoshikazhu Takada
Affiliation:
- School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, Hubei Province 430081,China
Keywords: Cancer incidence, cell membranes, inhibitors, lipoproteins, sPLA2-IIA, therapeutic strategy.
Abstract: Secretory phospholipase A2 group IIA (sPLA2-IIA) is an enzyme that hydrolyzes the sn-2 ester bond in glyceroacyl phospholipids present in lipoproteins and cell membranes. As many immunohistochemical studies reveal that the high expression of sPLA2-IIA in the tumorous tissue or plasma of cancer patients, though low expression in other cases, the enzyme is considered highly relevant with cancer development. Effort has been made to establish the mechanism of how sPLA2- IIA is involved in various cancers in order to understand its pathogenic role and to utilize it as a target for cancer diagnosis and therapy. This article specifically reviews recent studies regarding the relevance of sPLA2-IIA with various cancers and reported inhibitors of the protein.
Export Options
About this article
Cite this article as:
Chen Juan , Ye Long*, Sun Yu and Takada Yoshikazhu , A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer, Medicinal Chemistry 2017; 13 (7) . https://dx.doi.org/10.2174/1573406413666170209121317
DOI https://dx.doi.org/10.2174/1573406413666170209121317 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology Spectrophotometric Quantification of Bilirubin in Hemorrhagic Spinal Fluid using an Innovative Algorithm
Medicinal Chemistry The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Drug Metabolism Letters Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Heart Failure in South America
Current Cardiology Reviews MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol
Current Drug Targets - Cardiovascular & Hematological Disorders Gadolinium-based Imaging Contrast Agents
Current Medical Imaging Novel Strategies in the Ablation of Typical Atrial Flutter: Role of Intracardiac Echocardiography
Current Cardiology Reviews Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Current Vascular Pharmacology Chymase Inhibitors
Current Pharmaceutical Design Vascular Modeling from Volumetric Diagnostic Data: A Review
Current Medical Imaging New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued)